Market Brief

Indian Pharma Companies Improve on FDA Clearances, an Industrial Info Market Brief

The growth of India's pharmaceutical sector, which was stymied by frequent warning letters from the U.S. Food and Drug Administration (FDA), has seen some improvement recently, with many leading pharmaceutical units receiving nods from the authority. Divi's Laboratories' and Laurus Labs' plants in Andhra Pradesh and, most recently, Natco Pharma's active pharmaceutical ingredient (API) facility near Chennai passed through the FDA's audit with zero warning. The development is significant, given the fact that India is the largest provider of generic drugs globally and meets nearly 40% of the demand for generic drugs in the U.S. and 25% of the demand for all medicines in the U.K. Industrial Info is 831 pharmaceutical and biotech plant records in India, with over 3,500 functional management contacts. Click here for a list.

Released Thursday, July 18, 2019